Oppenheimer & Co’s Aquestive Therapeutics AQST Stock Holding History

Oppenheimer & Co’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$235K	Sell	50,747 -305	-0.6%	-$1.36K	﹤0.01%	1552
2026 Q2	$212K	Buy	51,052 +13,167	+35%	+$55.4K	﹤0.01%	1637
2026 Q1	$157K	Buy	+37,885	New	+$154K	﹤0.01%	1604
2025 Q4	–	Sell	-33,532	Closed	-$187K	–	1561
2025 Q3	$187K	Buy	+33,532	New	+$145K	﹤0.01%	1556

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Sugar Maple Asset Management Sister Bay, Wisconsin $175M AUM 16.33% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Daymark Wealth Partners Cincinnati, Ohio $4.41B AUM 22.52% 1-Year Est. Return

Oppenheimer & Co's AQST Position: Q3 2026 in Review

Oppenheimer & Co reduced its Aquestive Therapeutics (AQST) stake by 0.6% in Q3 2026, selling an estimated $1.36K and leaving 50,747 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #1552.

Oppenheimer & Co first reported a position in AQST in Q3 2025 and has held it in 4 quarters since. 51 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

Oppenheimer & Co held 50,747 shares of Aquestive Therapeutics worth $235K as of Q3 2026.
Oppenheimer & Co sold 305 Aquestive Therapeutics shares in Q3 2026, an estimated $1.36K.
Aquestive Therapeutics made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1552 holding.
Oppenheimer & Co first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 4 quarters since.
51 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.